Answers are grounded in this paper and cite their sources.
Introduction: Statins are beneficial for both primary and secondary prevention of cardiovascular disease in many patients at elevated risk. However, selection of patients most likely to respond and least likely to have adverse effects can benefit from refinement. While pharmacogenomic aspects of statins have been thoroughly evaluated, as yet there has been no major impact on patient care, although there is great potential that a precision medicine approach might one day enhance patient care.Areas covered: This paper provides a brief overview of genetic variants that influence statin responsiveness, together with newer information on genetic risk scores that combine numerous common DNA variants into a stronger prediction of cardiovascular risk reduction from statins. We also discuss a pharmacokinetic-based approach to aid in prediction and prevention of statin adverse effects.Expert commentary: While individual genetic variants appear to have statistically significant effects on lipid lowering by statins, such effects are often not clinically significant. However, evaluating simultaneously the cumulative effect of multiple common variants, along with relevant clinical factors, may provide a way forward that allows for better patient selection, and more precisely maximizing benefits while concurrently reducing the risk adverse effects.
No takes yet. Share an insight, caveat, or question.
Mehdar et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: